All In Biotech

Drug Trial Radar · NCT06930859

Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+) HER2-negative Stage II and III Breast Cancer in Real Clinical Practice in Russia

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

2,766

Planned (sponsor's estimate)

Start

Dec 3, 2025

Primary completion

Dec 31, 2032

Study completion Dec 31, 2032

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Apr 16, 2025

More drug trials from this sponsor

Design

Study type
Observational
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This prospective, observational, multicenter study aims at evaluating the efficacy of adjuvant ribociclib in combination with hormone therapy (aromatase inhibitor ± GnRH aginost) in various subgroups of patients with HR+HER2- stage II-III breast cancer in real clinical practice in Russia. Subgroup division will be based on the tumor grade, lymph node involvement, and the response to test hormone therapy. The study will consist of two cohorts: a prospective one with patients receiving adjuvant therapy with ribociclib combined with Aromatase inhibitors (AI), and a retrospective one with patients receiving adjuvant therapy with AI alone. Thus, both primary data collection and secondary use of data will be organized.

Conditions

  • Breast Cancer

Interventions

  • RibociclibDrug

    CDK4/6 inhibitor

  • LetrozoleDrug

    Aromatase inhibitor

  • AnastrozoleDrug

    Aromatase inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Invasive breast cancer-free survival (IBCFS) according to the Standardized Definitions for Efficacy End Points (STEEP) criteria in a prospective cohortTime frame: Months 36, 48, 60

Locations

49 sites in 1 country. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Arkhangelsk, Russia · Recruiting

  • Novartis Investigative Site

    Barnaul, Russia · Recruiting

  • Novartis Investigative Site

    Bryansk, Russia · Recruiting

  • Novartis Investigative Site

    Chelyabinsk, Russia · Recruiting

  • Novartis Investigative Site

    Irkutsk, Russia · Recruiting

  • Novartis Investigative Site

    Ivanovo, Russia · Recruiting

  • Novartis Investigative Site

    Izhevsk, Russia · Recruiting

  • Novartis Investigative Site

    Kemerovo, Russia · Recruiting

  • Novartis Investigative Site

    Khabarovsk, Russia · Recruiting

  • Novartis Investigative Site

    Khanty-Mansiysk, Russia · Recruiting

  • Novartis Investigative Site

    Khimky, Russia · Recruiting

  • Novartis Investigative Site

    Kirov, Russia · Recruiting

  • Novartis Investigative Site

    Krasnodar, Russia · Recruiting

  • Novartis Investigative Site

    Krasnoyarsk, Russia · Recruiting

  • Novartis Investigative Site

    Lipetsk, Russia · Recruiting

  • Novartis Investigative Site

    Moscow, Russia · Recruiting

  • Novartis Investigative Site

    Moscow, Russia · Recruiting

  • Novartis Investigative Site

    Moscow, Russia · Recruiting

  • Novartis Investigative Site

    Moscow, Russia · Recruiting

  • Novartis Investigative Site

    Moscow Region Balas, Russia · Recruiting

  • Novartis Investigative Site

    Perm, Russia · Recruiting

  • Novartis Investigative Site

    Pyatigorsk, Russia · Recruiting

  • Novartis Investigative Site

    Rostov-on-Don, Russia · Recruiting

  • Novartis Investigative Site

    Saint Petersburg, Russia · Recruiting

  • Novartis Investigative Site

    Saint Petersburg, Russia · Recruiting

  • Novartis Investigative Site

    Saint Petersburg, Russia · Recruiting

  • Novartis Investigative Site

    Samara, Russia · Recruiting

  • Novartis Investigative Site

    Saransk, Russia · Recruiting

  • Novartis Investigative Site

    Saratov, Russia · Recruiting

  • Novartis Investigative Site

    Sestroretsk, Russia · Recruiting

  • Novartis Investigative Site

    Shakhty, Russia · Recruiting

  • Novartis Investigative Site

    Tambov, Russia · Recruiting

  • Novartis Investigative Site

    Tomsk, Russia · Recruiting

  • Novartis Investigative Site

    Tver', Russia · Recruiting

  • Novartis Investigative Site

    Tyumen, Russia · Recruiting

  • Novartis Investigative Site

    Ufa, Russia · Recruiting

  • Novartis Investigative Site

    Vladikavkaz, Russia · Recruiting

  • Novartis Investigative Site

    Vladivostok, Russia · Recruiting

  • Novartis Investigative Site

    Volgograd, Russia · Recruiting

  • Novartis Investigative Site

    Voronezh, Russia · Recruiting

Showing 40 of 49 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.